| PET-CT surveillance versus neck dissection in advanced head and neck cancer H Mehanna, WL Wong, CC McConkey, JK Rahman, M Robinson, ... New England Journal of Medicine 374 (15), 1444-1454, 2016 | 554 | 2016 |
| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 541 | 2020 |
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ... The lancet oncology 14 (10), 933-942, 2013 | 488 | 2013 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 239 | 2019 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 224 | 2020 |
| Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others JMS Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ... JNCI: Journal of the National Cancer Institute 108 (9), djw050, 2016 | 190 | 2016 |
| PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data PN Aguiar Jr, RA De Mello, P Hall, H Tadokoro, G Lima Lopes Immunotherapy 9 (6), 499-506, 2017 | 180 | 2017 |
| Cost effectiveness modelling for health technology assessment: a practical course R Edlin, C McCabe, C Hulme, P Hall, J Wright Springer International Publishing, 2015 | 123* | 2015 |
| Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ... The Lancet Oncology 23 (1), 149-160, 2022 | 100 | 2022 |
| Economic evaluation of genomic test–directed chemotherapy for early-stage lymph node–positive breast cancer PS Hall, C McCabe, RC Stein, D Cameron Journal of the National Cancer Institute 104 (1), 56-66, 2012 | 94 | 2012 |
| Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer R Bell, J Brown, M Parmar, M Toi, T Suter, GG Steger, X Pivot, J Mackey, ... Annals of Oncology 28 (4), 754-760, 2017 | 92 | 2017 |
| OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. RC Stein, JA Dunn, JMS Bartlett, AF Campbell, A Marshall, P Hall, ... Health Technology Assessment (Winchester, England) 20 (10), 1, 2016 | 77 | 2016 |
| Current perspective–trastuzumab PS Hall, DA Cameron European Journal of Cancer 45 (1), 12-18, 2009 | 77 | 2009 |
| AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled … P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ... J Clin Oncol 36 (15_suppl), 1007, 2018 | 75 | 2018 |
| PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned … H Mehanna, CC McConkey, JK Rahman, WL Wong, AF Smith, C Nutting, ... Health Technology Assessment, 2017 | 73 | 2017 |
| Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence PS Hall, C Hulme, C McCabe, Y Oluboyede, J Round, DA Cameron Pharmacoeconomics 29, 415-432, 2011 | 71 | 2011 |
| Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal … PS Hall, D Swinson, DA Cairns, JS Waters, R Petty, C Allmark, S Ruddock, ... JAMA oncology 7 (6), 869-877, 2021 | 70 | 2021 |
| Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data PS Hall, P Hamilton, CT Hulme, DM Meads, H Jones, A Newsham, J Marti, ... British journal of cancer 112 (5), 948-956, 2015 | 68 | 2015 |
| Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. PS Hall, D Swinson, JS Waters, J Wadsley, S Falk, R Roy, T Tillett, J Nicoll, ... Journal of Clinical Oncology 37 (15_suppl), 4006-4006, 2019 | 67 | 2019 |
| The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation L Rooshenas, LJ Scott, JM Blazeby, CA Rogers, KM Tilling, S Husbands, ... Journal of clinical epidemiology 106, 108-120, 2019 | 63 | 2019 |
Claire HulmeProfessor of Health Economics, University of ExeterVerified email at exeter.ac.uk
